Announcement on Convening the Q3 2025 Performance Briefing
Filed with SSE · · 3 pages · Chinese
Zhuzhou Qianjin Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhuzhou Qianjin Pharmaceutical
- Announcement on Main Operating Data for Q3 2025
- Announcement on the Implementation of Issuance of Shares and Payment in Cash for Asset Purchase and Related Party Transactions and Changes in Capital Shares
- Announcement on Amendment to Report on Purchasing Assets through Issuance of Shares and Cash Payment and Related Party Transaction
- Announcement on Transfer of Underlying Assets Related to the Company's Issuance of Shares and Payment of Cash to Purchase Assets and Related Party Transactions
- Announcement on Obtaining Registration Approval from the China Securities Regulatory Commission for Issuance of Shares and Cash Payment for Asset Acquisition and Related Party Transactions
Later from Zhuzhou Qianjin Pharmaceutical
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
- Announcement on Outline of the Q3 2025 Performance Briefing
- Announcement on Changing the Independent Financial Advisor for Continuous Supervision
- Announcement on Resolutions of the 15th Meeting of the 11th Board of Directors
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
Follow Zhuzhou Qianjin Pharmaceutical into a list and get an email when it puts out news.
Follow Zhuzhou Qianjin Pharmaceutical